The cognitive decline was reversed by Abeta immunotherapy in young 3xTg-AD mice [63], indicating that the reduction of soluble Abeta level is sufficient for the prevention of memory impairment in the early stage of Abeta pathology. This evidence concerns the gene APP and Alzheimer disease.